Catalyst Repository | Immunovant Inc. Common Stock

Immunovant Inc. Common Stock

(NASDAQ:IMVT)

Description

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

IMVT Overview

None
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Previous Close
$22.2800
Previous Close Volume
920660